Claims for Patent: 9,631,198

Summary for Patent: 9,631,198

Title:	Chimeric promoters capable of mediating gene expression in plants upon pathogen infection and uses thereof
Abstract:	Described are synthetic promoters capable of mediating gene expression in plants upon pathogen infection. Furthermore, recombinant genes and vectors comprising said chimeric promoters as well as host cells transformed with such chimeric promoters, recombinant genes, or vectors are provided. Additionally, diagnostic compositions and kits comprising such chimeric promoters, recombinant genes, vectors or cells are described. Provided are further methods for the identification of compounds being capable of activating or inhibiting genes that are specifically expressed in plants upon pathogen infection employing the above described means. Furthermore, transgenic plant cells, plant tissue, and plants containing the above-described chimeric promoters, recombinant genes, and vectors as well as the use of the aforementioned chimeric promoters, recombinant genes, vectors and/or compounds identified by the method of the invention in plant cell and tissue culture, plant breeding, and/or agriculture are described.
Inventor(s):	Kirsch; Christoph (Cologne, DE), Logemann; Elke (Pulheim-Dansweiler, DE), Hahlbrock; Klaus (Freiburg, DE), Rushton; Paul (Brookings, SD), Somssich; Imre (Cologne, DE)
Assignee:	Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V. (Berlin, DE)
Application Number:	13/930,307
Patent Claims:	1. An isolated cis-acting element sufficient to direct pathogen-elicitor-specific expression, pathogen-infection-specific expression, or both, consisting of the nucleotide sequence of SEQ ID NO: 8 or 9. 2. A chimeric promoter capable of local gene expression in plants of an operably linked nucleic acid sequence, wherein the expression is induced by a pathogen elicitor treatment, a pathogen infection, or both, wherein the chimeric promoter comprises: (i) at least two cis-acting elements sufficient to direct: the pathogen-elicitor-specific expression of the nucleic acid sequence, the pathogen-infection-specific expression of the nucleic acid sequence, or both, wherein two of the at least two cis-acting elements are each a cis-acting element consisting of the nucleotide sequence of SEQ ID NO: 8 or 9, and (ii) a minimal promoter, wherein each of said two of the at least two cis-acting elements consisting of the nucleotide sequence of SEQ ID NO: 8 or 9 are separated by only a spacer of from 4 to 10 base pairs. 3. The chimeric promoter according to claim 2, further comprising at least one additional cis-acting element, wherein said at least one additional cis-acting element consists of the nucleotide sequence selected from the group consisting of the nucleotide sequences of one of SEQ ID NO: 1-16. 4. The chimeric promoter of claim 3, wherein said chimeric promoter comprises at least one of homo- and hetero-multimeric forms of at least one of the at least two cis-acting elements and said at least one additional cis-acting element. 5. The chimeric promoter of claim 4, wherein said homo- and/or hetero-multimeric form is a dimer or a tetramer. 6. The chimeric promoter of claim 3, wherein at least two of the elements, selected from said at least two cis-acting elements and said at least one additional cis-acting element, are separated by a spacer of about 50 to about 1000 base pairs. 7. The chimeric promoter according to claim 2, wherein at least one of the at least two cis-acting elements comprises two copies of the nucleotide sequence of SEQ ID NO: 8 or 9. 8. The chimeric promoter according to claim 7, further comprising two copies of the nucleotide sequence of SEQ ID NO: 3 or 4. 9. The chimeric promoter of claim 2, wherein the minimal promoter is a minimal promoter from a promoter selected from the group consisting of a CaMV35S promoter, a CHS promoter, a PR1 promoter, and a hcbt2 promoter. 10. The chimeric promoter of claim 2, wherein the distance between at least one of said at least two cis-acting elements and said minimal promoter is 12 to 300 base pairs. 11. The chimeric promoter of claim 2, wherein the distance between said at least two cis-acting elements and said minimal promoter is 25 to 70 base pairs. 12. The chimeric promoter of claim 2, wherein the distance between said at least one cis-acting element and said minimal promoter is 40 to 60 base pairs. 13. A recombinant gene comprising the chimeric promoter of claim 2. 14. The recombinant gene of claim 13, wherein at least one of the at least two cis-acting elements is located in the 5'- or 3'-untranslated region or in an intron of the recombinant gene. 15. The recombinant gene of claim 13, wherein the chimeric promoter is operatively linked to a heterologous DNA sequence, and wherein said heterologous DNA sequence encodes a (poly)peptide, a cytotoxic protein, an antibody, an antisense RNA, a sense RNA, a ribozyme, a transcription factor, a protease, a nuclease, a lipase, or a polymerase. 16. A vector comprising the chimeric promoter of claim 2 or the recombinant gene of claim 13. 17. A transgenic plant cell comprising the chimeric promoter, a recombinant gene comprising the chimeric promoter, or a vector comprising the chimeric promoter of claim 2. 18. A transgenic plant or a plant tissue comprising the transgenic plant cell of claim 17. 19. A harvestable part of a transgenic plant of comprising the transgenic plant cell of claim 17. 20. A propagation material of a transgenic plant of comprising the transgenic plant cell of claim 17.

Details for Patent 9,631,198

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2018-11-12
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2018-11-12
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2018-11-12